US FDA grants approval to Incyte’s Opzelura cream for vitiligo treatment
Pharmaceutical Technology
JULY 19, 2022
As per results at week 24, nearly 30% of subjects receiving Opzelura attained ?75% 75% improvement from baseline in the facial Vitiligo Area Scoring Index (F-VASI75), the primary endpoint, versus nearly 8% and 13% of subjects who received vehicle in TRuE-V1 and TRuE-V2, respectively.
Let's personalize your content